Does starting MS drug early make a difference? austrian study aims to find out
NCT ID NCT05776888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observes 106 Austrian patients with relapsing multiple sclerosis who are already taking Ofatumumab (Kesimpta). Researchers compare those who started the drug early versus later, tracking disease activity over two years. The goal is to see if early treatment leads to fewer relapses and less disability progression in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ofatumumab (Kesimpta)
- What this could lead to
- If successful, this study could show that starting Ofatumumab earlier leads to better control of MS relapses and disability progression.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient differences. It only tracks outcomes, not testing a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.